A Costly Chapter for Innovation
Founded with research roots at the University of Connecticut, ImStem launched clinical trials in Georgia in 2021, aiming to push stem cell therapies into mainstream medicine. But the legal brawl drained its resources, leaving behind the debts now driving its bankruptcy.
Despite the court losses, ImStem previously insisted the disputed patents were “not related to our current product and clinical development,” signaling that its Chapter 11 bid is as much about restructuring finances as salvaging its scientific future.
Legal Representation
ImStem is represented in the bankruptcy by Andrea M. O’Connor of Shatz Schwartz and Fentin PC.
